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ABSTRACT
Individuals respond to the same medications in diverse manners. Polymorphism in drug-metabolizing enzymes plays a very important role in 
interindividual variations in drug medical care. Hence, the aim was to review reported cases of genetic polymorphisms among the antiretrovirals, 
especially efavirenz, a non-nucleoside reverse transcriptase inhibitor, used in the management of human immunodeficiency virus infection/acquired 
immune deficiency syndrome, which is metabolized primarily by the CYP2B6 enzyme. Several previous publications on genetic polymorphism 
associated with the antiretrovirals of patients on highly active antiretroviral therapy were selected and carefully reviewed to evaluate their correlation 
and or conflict of interest among different authors. The existence of polymorphisms on the CYP2B6 gene that encodes for expression of the enzyme, 
among other factors responsible for efavirenz metabolism, is a significant determinant of inter-individual variability in pharmacokinetics and 
pharmacodynamic response to the drug used in clinical practice. Furthermore, plasma levels of efavirenz and phenotypic difference were observed, 
are contributing factors as to the rate of antiretroviral adverse drug reactions. Following the review, studies showed similar outcomes relating to 
efavirenz pharmacokinetics and polymorphism; hence, patients that display genetic polymorphism on efavirenz may likely develop the same on other 
therapeutic agents metabolized by the CYP450 enzymes or other polymorphic enzymes.
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INTRODUCTION
Acquired immunodeficiency syndrome is a spectrum of conditions 
caused by the human immunodeficiency virus [1,2]. Following 
the invasion of the virus into the host immune system, an infected 
individual may not notice any symptoms or may just notice a brief 
period of influenza-related symptoms [3]. This initial stage is followed 
by a long period, also without symptoms [4]. As the virus replicates 
more in the system, the infection progresses and interferes with the 
cells of the host immune system. This increases the risk of developing 
certain infections, known as “opportunistic infections,” including 
tuberculosis and certain kind of cancerous tumors that affect people 
who had stable immune systems [3]. The late phase of infection has 
accompanying symptoms and is referred to as AIDS, which is usually 
linked with unexplainable loss of weight [4]. It has been reported that 
AIDS can be prevented through the use of a condom (protected sex), 
advocacy on the safe use of needles and sharp objects especially in 
the hospital and medical laboratories, male circumcision to prevent 
abhorring of bacteria or other infectious organisms in the male genitals 
and immediate treatment of infected persons [4].
In the Joint United Nations Programme on HIV/AIDS global fact sheet 
of 2016, it was reported that about 36.7 million people were living with 
HIV and this resulted in about 1 million mortalities globally [5,6].
AIDS is well-defined in terms of either CD4+ T cell count, which is <200/µL 
cells or the occurrence of specific diseases related to the infection. In the 
absence of antiretroviral therapy (highly active antiretroviral therapy), 
it is known that about half of people infected with the virus may 
develop AIDS within 10 years period following viral infection. Some of 
the frequent symptoms or conditions that show the development of AID 
include cachexia (20%), pneumonia (40%), esophageal candidiasis, and 
respiratory tract infection that are persistent [7]. People infected with 
the AIDS stage have an increased tendency to develop certain cancers 
induced by the virus such as Kaposi’s sarcoma, primary central nervous 
system lymphoma, conjunctival, and cervical cancer [7-9]. Various 
reports have it that HIV is rapidly transmitted by raw sexual contact, 
homosexuals, significant exposure to body fluids from HIV-infected 
persons and from mother-to-child during pregnancy, at birth, or during 
breastfeeding, which is known as vertical HIV transmission [10]. It was 
reported in 2008 that vertical HIV transmission accounted for almost 
90% of HIV/AIDS cases in children. With proper antiretroviral therapy, 
the risk of mother-to-child transmission of HIV infection can be reduced 
to about 1% [10-12].
Current HIV/AIDS treatment and gene mutation
The World Health Organization recommends the use of highly active 
antiretroviral therapy (HAART) in sub-Saharan African countries, 
including Nigeria [13]. HAART has been reported to slow the 
progression of HIV/AIDS infection. More than 6.6 million people in 
2010 were reported to be taking HAART regimens in developing 
countries. The HAART regimen tackles all the stages of the HIV life 
cycle and these antiretrovirals are classified on this basis. Some of the 
commonly used classes of antiretroviral drugs include fusion inhibitors, 
nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase 
inhibitors, protease inhibitors, and maturation inhibitors [14-16]. HIV 
life cycle is as short as 1½ day from point of viral entry into the cells 
of the host, throughout replication, during cell assembly, and release 
of new viral particles to infect other surrounding immune cells [17]. 
The short life cycle of the virus and its high error rate cause the virus 
to mutate very rapidly, resulting in the high genetic variability of HIV. 
Hence, HIV has different subtypes such as HIV-1 and HIV-2. Although 
most of the mutations are inferior to the parent virus and do not convey 
any advantage, some of them have natural selection superiority to their 
parent and this can enable HIV to break the human immune system 
defense and resist some antiretroviral drugs [18].
Combinations of antiretrovirals are the mainstay of HIV/AIDS therapy 
because it creates multiple hindrances to HIV replication at a different 
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stage of the viral life cycle, thereby keeping the number of new viral 
particles low and also reduce the possibility of viral cell mutation. If 
a mutation that conveys resistance to one of these drugs arises, the 
other drugs in the regimen will continue to suppress the replication 
of that mutation. With rare exceptions, no individual antiretroviral 
drug has been demonstrated to suppress an HIV infection for a long 
duration; therefore, these agents must be taken in combinations 
to have a lasting effect. As a result, the standard of HIV/AIDS care 
is to use combinations of antiretroviral therapy known as a triple 
cocktail [19,20]. It has been reported that the primary causes of death 
from HIV/AIDS are due to the HIV-related opportunistic infections 
and tumors as a result of uncontrolled genetic polymorphism, both 
of which are frequently the result of the progressive failure of the 
immune system [8,21,22].
Pharmacogenetics and polymorphism
The concept of pharmacogenetics is concerned with individual variations 
to drug or medications response, which could be due to insertions, 
deletions, duplications, or multiplication, and point mutations within 
the genes coding for the enzymes responsible in metabolizing the 
drug in question. These genetic changes can give rise to enzymes with 
altered or deficient or increased activity resulting in compromised drug 
metabolism as well as environmental carcinogens such as poly saturated 
or chlorinated hydrocarbons [23]. Pharmacogenetic polymorphism 
has also been reported to occur, but within a population, a single gene 
responsible for producing a metabolizing enzyme has a variant allele 
at the same locus and more than one phenotype with regards to drug 
interaction with the host receptors; the frequency of the least common 
allele being >1% [24].
Gene polymorphism is a distinction in deoxyribonucleic acid (DNA) 
sequence among individual patients, groups, races or ethnicity. Sources 
such as single nucleotide polymorphisms (SNPs), sequence duplications, 
insertions, deletions, and recombination are the likely cause of gene 
polymorphism [25,26]. Genetic polymorphism is also the result of 
probability processes or could be induced by external agents such 
as radiation or other microorganisms such as viruses [27-29]. These 
genetic mutations are some forms of genetic polymorphism that 
involve a permanent modification within the sequence of that polymer 
that produces the gene, specified that the sequence differs from what 
is found in the majority of individuals in a given population [30]. 
Mutations change polymer (DNA) building block (base pair) at any 
point to an oversized phase of a chromosome that features multiple 
genes [31,32].
Genetic polymorphism of enzymes involved in drug metabolism has 
been reported to play key roles for inter-individual variations in clinical 
practice. This variability is of current significance throughout the drug 
development and importance for routine drug prescription. Many 
different drugs enclose pharmacogenomic labels where genotyping 
before prescription has been necessary or recommended based on 
individual differences to drug response. Predictive genotyping of drug-
metabolizing genes can thus help to design individualized, less toxic, 
efficacious, and more cost-effective pharmacotherapy [33].
Efavirenz pharmacokinetics and the cytochrome P450 enzyme 
system
Both the NRTIs and NNRTIs inhibit the reverse transcriptase enzyme 
(Fig. 1). The reverse transcriptase is an essential viral enzyme 
that transcribes proviral ribonucleic acid into DNA. NRTIs such as 
zidovudine and lamivudine act by binding to the enzyme active site, 
while the NNRTIs like efavirenz act allosterically by binding to a distinct 
site away from the enzyme’s active site known as the NNRTI pocket. 
Efavirenz is metabolized chiefly by the CYP2B6 enzyme [34] and it has 
been reported to also play a major role in the biotransformation of some 
other therapeutically important drugs, including cyclophosphamide, 
bupropion, ketamine, propofol, and artemisinin [35-38]. Efavirenz is 
stable, as there is no reported significant change in drug content and 
drug release after prolonged storage [39].
Efavirenz is known to induce its biotransformation (metabolism) and 
this auto-induction process was observed to give a three-fold increase 
in the oral clearance after multiple efavirenz administration [40]. It 
has also been shown that mild-dosing interval plasma concentration 
of efavirenz <1 mg/L has been associated with therapeutic failure and 
this could lead to the development of HIV viral resistance, on the other 
hand, efavirenz plasma concentration >4 mg/L can increase the risk of 
adverse effects, including neuropsychiatric effects such as drowsiness, 
dizziness, and confusion [41].
A Swiss HIV cohort study, conducted by Margalida et al. (2005), 
evaluated the CYP2B6 polymorphic allele as a pharmacogenetic marker 
of efavirenz and nevirapine pharmacokinetics and efavirenz toxicity 
in about 167 subjects receiving efavirenz and 59 receiving nevirapine. 
The drug concentrations were measured in plasma and peripheral 
blood mononuclear cells from the same sample. Neuropsychological 
toxicities of efavirenz (sleep disorders, mood disorders, and fatigue) 
were assessed using a standardized questionnaire. They concluded 
that CYP2B6 516TT was associated with greater efavirenz intracellular 
plasma concentration and greater plasma exposure to nevirapine [42].
In another study, the CYP2D6*3*4*9*10*17 and *29 alleles in a Nigerian 
population subjected to dextromethorphan and its O-demethylated 
metabolite, dextrorphan was reported by Ebeshi et al., 2011. The 
frequency of the CYP2D6*4 allele was found to be 2%, 8%, and 3% in 
Hausa, Igbo, and Yoruba speaking subjects, respectively. The average 
frequency of 4% for CYP2D6*4 implies that there is a very low likelihood 
of poor metabolizers due to this allele in Nigerian populations. The 
most common alleles were CYP2D6*17 and CYP2D6*29. The frequency 
of the CYP2D6*17 allele was not significantly different in the three 
populations (p>0.05) occurring at 18%, 14%, and 22% in the Hausa, 
Igbo, and Yoruba, respectively. Furthermore, the frequency of the 
CYP2D6*29 allele was found to be 10%, 20%, and 10% in the Hausa, 
Igbo, and Yoruba population, respectively [43].
The Cytochrome P4502B6 enzyme
The CYP2B6 is a highly polymorphic isoenzyme encoded by the CYP2B6 
gene. Numerous allelic forms have been reported to be responsible 
for the proteins with varying degrees of enzyme activity. In particular, 
the CYP2B6*6 allele variant of the CYP2B6 gene is associated with its 
decreased enzyme activity. An example of SNPs with CYP2B6 with 
decreased enzymatic activity is the variant 516G/T relating to the 
CY2B6*6 allele. Phenotypically, the TT homozygotes are reported to 
be poor metabolizers, (highly toxic drugs – reduction of the dose is 
recommended), the GT heterozygotes have been characterized by 
immediate activity (intermediate metabolizers) of the CYP2B6 enzyme 
(normal therapeutic dose of the drug is recommended), and the GG 
homozygotes are extensive or rapid metabolizers (increased dose of 
Fig. 1: Structure of efavirenz
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Ethnicity variability of efavirenz metabolism
In a population pharmacokinetic study, Csajka et al. (2003) reported 
pronounced interindividual differences in efavirenz bioavailability and 
an inverse correlation between average drug exposure and HIV viral 
load, as well as the trend with central nervous system toxicity [45]. 
These same investigators found that black populations had higher 
efavirenz plasma concentrations due to a significant reduction in 
clearance rate compared to other ethnic groups. Efavirenz is a key drug 
in the first-line management of HIV/AIDS treatment (HAART), the 
availability of CYP2B6 allele frequency data in different populations, 
especially in populations with high HIV infection risk (such as Africans, 
Asians, and African-Americans) is of great interest (http://www.
unaids.org). CYP2B6 polymorphism has been shown to have clinical 
relevance in HIV-infected patients treated with efavirenz, but it is 
increasingly being recognized for other drug substrates metabolized 
by this enzyme [46].
Several methods have been developed, including high-performance 
liquid chromatography, polymerase chain reaction, and restriction 
fragment length polymorphism, to quantify the serum levels 
and polymorphic nature of antiretrovirals among patients on 
HAART [47,48].
RESULTS SUMMARY AND DISCUSSION
Several journal articles were reviewed on pharmacogenetic 
polymorphism, observed causes of major polymorphism and 
phenotypic differences are presented Tables 1-6.
They concluded that the allelic distribution of CYP2B6*6 appears 
comparable in Nigerian populations and other African populations 
but significantly higher than the Caucasian and Asian populations, 
indicating that Nigerian populations may be at risk of adverse reactions 
if given the similar or same dose of efavirenz or other substrates of 
CYP2B6. They further stated that CYP2B6 genotyping may be useful 
to complement an individualization strategy based on plasma drug 
determinations to increase the safety and tolerability of efavirenz. 
The CYP2B6*6 genotype and allele frequencies showed no significant 
deviations from Hardy–Weinberg equilibrium (p>0.05) in Nigeria 
Population. However, the 40% obtained in this study was seen to 
be consistent with those found in other African populations with 
frequencies up to 49% and 47% in Ghanaian and African-American 
population, respectively, but higher when compared to frequencies of 
25% and 18% in Caucasians and Orientals population [43,49].
It was concluded that the observed and expected genotype and allele 
frequencies did not show statistically significant differences compared 
to those expected under the Hardy–Weinberg equilibrium and that 
genetic polymorphism revealed in the Ukrainian population is the 
basis for recommending genetic testing for the 516G/T polymorphism 
for drug therapy optimization with drugs which are CYP2B6 gene 
substrates [50].
They observed that the high prevalence of the CYP2B6*6 (T) and 
the homozygous genotype CYP2B6*6/*6 (516TT) in the Kenyan 
populations were consistent with reports from most sub-Saharan 
African populations [52]. Studies covering HIV/AIDS patients in 
East Africa showed the influence of CYP2B6 516 G>T not only on the 
pharmacokinetics of efavirenz and nevirapine but also on clinical 
outcomes [53,54]. Previous studies has seen the incorporation 




Males 0.54 0.39 0.07
Females 0.58 0.36 0.06
Total 0.56 0.38 0.06
Table 2: The observed and expected distribution of CYP2B6 516 
G/T pharmacogenetically important polymorphism Ukrainian 
populations, distribution of the 516G/T polymorphism of the 
CYP2B6 gene
Males, n Female, n Total, n (%)
GG 27 30 57 (56)
GT 16 22 38 (37)
TT 5 2 7 (7)
Statistics: x2=0.656, df=2, p>0.05 (χ2=Pearson’s criterion, df-degree of freedom, 
p-significant level) [50]







Table 1: Genotypes and alleles frequencies of CYP2B6*6 in Nigerian populations (Ebeshi et al., 2011)
CYP2B6*6 genotype/allele frequencies Hausa N/total (%) Ibo N/total (%) Yoruba N/total (%) Mean pooled N/pooled total (%)
EM (G/G) 37/98 (38) 43/101 (43) 34/101 (34) 114/300 (38)
IM (G/T) 39/98 (40) 40/101 (40) 50/101 (50) 129/300 (43)
PM (T/T) 20/98 (20) 18/101 (18) 17/101 (17) 55/300 (18)
Allele (T) 82/196 (42) 72/202 (36) 84/202 (42) 238/600 (40)
EM: Extensive metabolizers, IM: Intermediate metabolizers, PM: Poor metabolizers, G: Guanine, T: Thymine
Table 5: The observed and expected genotype frequencies of 








Statistics: χ2=0.054, df=2, p>0.05
Table 6: The frequency of allelic variants of CYB2B6 observed in 
the Bantu and Nilotic populations of Kenya [51]
Allele Prevalence (%)




p Mean 95% CI
*6 34.5 35.2 37.1 0.871 35.5 31.8–39.5
n 168 256 178
n=Total number of alleles
the drug is recommended). The CYP2B6 enzyme metabolizes several 
currently prescribed medications, including efavirenz, bupropion, and 
cyclophosphamide [44].
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of CYP2B6 516 G>T genotypes in pharmacokinetic modelling of 
efavirenz dosing interval which have led to dosage reduction in African 
population. These observations should is of great interest since the 
majority of HIV/AIDS patients in Kenya are on efavirenz-based first-line 
antiretroviral therapy [52,55].
CONCLUSION
Efavirenz’s clinical relevance cannot be overemphasized. Following 
the above reviews, several studies have been conducted around the 
world on efavirenz pharmacokinetics and polymorphism with similar 
outcomes, including Nigeria; hence, patients with a polymorphism 
on efavirenz pharmacokinetics may likely develop the same on other 
pharmacotherapeutic agents metabolized by the CYP450 enzymes or 
other metabolic enzymes.
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